Home Healthcare Medical Devices Aortic Valve Replacement Market

Aortic Valve Replacement Market Size, Share & Trends Analysis Report By Surgery Type (Minimal Invasive Surgery, Open Surgery), By End-Use (Hospital, Ambulatory Surgical Centres) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: August 24, 2026 | Author: Debashree Bora | Format:

Aortic Valve Replacement Market Size & Growth Analysis

The global aortic valve replacement market size was valued at USD 18.10 billion in 2025 and is projected to grow from USD 20.64 billion in 2026 to USD 58.89 billion by 2034, registering a CAGR of 14% during the forecast period from 2026 to 2034. Europe dominated the aortic valve replacement market with a market share of 38.6% in 2025.

Aortic valve replacement is a medical procedure used to replace a damaged or diseased aortic valve that cannot function properly. The procedure may involve replacing the valve with a mechanical valve, a biological tissue valve, or another suitable replacement device. It is commonly performed to treat conditions such as severe aortic stenosis or aortic valve regurgitation. Aortic valve replacement helps restore normal blood flow from the heart, reduce symptoms, improve heart function, and support better quality of life for eligible patients.

Aortic Valve Replacement Market Key Takeaways

Global Market Size & Growth

  • 2025 Market Size: USD 18.10 Billion
  • 2026 Market Size: USD 20.64 Billion
  • 2034 Projected Market Size: USD 58.89 Billion
  • Forecast Period: 2026-2034
  • Base Year: 2025
  • Market CAGR (2026-2034): 14%

Regional Insights

  • Largest Regional Market (2025): Europe
  • Europe Market Share (2025): 38.6%
  • Fastest-Growing Region: North America
  • North America CAGR (2026-2034): 9.1%

Segment Insights

  • By Surgery
    • Leading Segment: Minimal Invasive Surgery
    • Market Share in 2025: 64.7%
  • By End-Use
    • Fastest growing segment: Ambulatory Surgical Centres
    • CAGR: 9.6% (2026-2034)
Aortic Valve Replacement Market Size

Download a Free Sample To learn more about this report,

Aortic Valve Replacement Market Trends

TAVR Makes Valve Replacement Less Invasive

The aortic valve replacement market is shifting toward less invasive treatment as more patients become eligible for transcatheter aortic valve replacement (TAVR). Instead of opening the chest, TAVR allows doctors to place a replacement valve through a catheter. This can make treatment easier for selected patients and may reduce the recovery burden associated with open-heart surgery. Growing clinical evidence and improvements in valve technology are supporting aortic valve replacement market growth.

  • For instance, in May 2025, the U.S. FDA approved Edwards Lifesciences' SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA systems for certain patients with severe aortic stenosis who have no symptoms. The decision expanded the use of TAVR to an earlier stage of the disease and was supported by results from the EARLY TAVR trial.

Earlier Intervention Creates New Treatment Opportunities

Aortic valve replacement is also moving toward earlier intervention for carefully selected patients rather than waiting until symptoms become severe. This change is encouraging doctors to assess patients more closely and consider factors such as disease progression, age, surgical risk, and overall health when deciding on treatment. As treatment options broaden, the aortic valve replacement market size is benefiting from greater use of both transcatheter and surgical valve replacement.

  • For instance, in April 2025, the FDA approved an expanded indication for Edwards' SAPIEN 3 platform covering patients with asymptomatic severe aortic stenosis who are considered appropriate for TAVR. The decision reflected growing evidence that earlier intervention can provide benefits for selected patients and further expanded the role of transcatheter valve replacement.

Aortic Valve Replacement Market Dynamics

Market Drivers

Growing Burden of Aortic Stenosis and Increasing Adoption of Minimally Invasive Procedures

The market is being supported by the growing need to treat severe aortic valve disease, particularly aortic stenosis among older adults. Alongside conventional surgical aortic valve replacement, transcatheter aortic valve replacement is becoming an important treatment option for appropriate patients because it can replace the diseased valve without conventional open-heart surgery. Advances in valve design and delivery systems are helping expand treatment options and supporting aortic valve replacement market demand.

  • For instance, in August 2025, the U.S. FDA approved an expanded indication for Medtronic's Evolut transcatheter aortic valve systems, allowing Redo-TAVR in patients with a failed previously implanted transcatheter aortic valve who were considered at high or greater risk for open surgical therapy. The approval expanded the potential use of valve-in-valve treatment for patients whose previous TAVR had failed.

Market Restraints

High Procedure Costs and Complex Patient Selection

The market faces pressure from the high cost of valve replacement procedures, specialized cardiac facilities, imaging requirements, and post-procedure monitoring. Treatment selection is also complex because physicians must consider age, surgical risk, anatomy, life expectancy, valve durability, and other medical conditions when deciding between surgical and transcatheter replacement.

  • For instance, in April 2026, CMS approved clinical studies investigating newer TAVR technologies, including the PARADIGM Trial evaluating the DurAVR valve and the STAR Trial evaluating TAVR in patients with symptomatic severe aortic stenosis. Continued clinical evaluation reflects the extensive evidence required before newer valve technologies can be adopted broadly.

Market Opportunities

Expansion of Valve-in-Valve Procedures and Next-Generation TAVR Technologies

The market has significant opportunities as newer transcatheter valves and valve-in-valve procedures expand treatment possibilities for patients who have previously received bioprosthetic or transcatheter valves. Improvements in valve positioning, hemodynamics, delivery systems, and patient-specific treatment planning are shaping important aortic valve replacement market trends.

  • For instance, in August 2025, the FDA expanded the indication for Medtronic's Evolut PRO+, Evolut FX, and Evolut FX+ systems to treat patients with failed surgical or transcatheter bioprosthetic aortic valves who were at high or greater risk from open-heart surgery. The decision created an additional treatment pathway for patients requiring repeat valve replacement.

Market Challenges

Balancing Minimally Invasive Treatment With Long-Term Valve Durability

The market continues to face the challenge of providing less-invasive procedures while ensuring that replacement valves remain safe and effective over the long term. This is particularly important as TAVR is increasingly considered for younger and lower-risk patients, who may live long enough to require another valve intervention. Physicians therefore need to balance faster recovery and lower procedural invasiveness against valve durability and future treatment options.

  • For instance, in January 2025, results from the EARLY TAVR randomized trial showed that early TAVR in patients with asymptomatic severe aortic stenosis reduced the combined risk of death, stroke, or unplanned cardiovascular hospitalization compared with clinical surveillance. The study included 901 patients, with a primary endpoint occurring in 26.8% of the TAVR group versus 45.3% of the surveillance group during a median follow-up of 3.8 years.

Aortic Valve Replacement Market Segmentation Analysis

By Surgery

Minimal Invasive Surgery Segment Led the Market with a 64.7% Share in 2025

Minimal invasive surgery accounted for the largest share of the aortic valve replacement market in 2025, representing 64.7% and an estimated value of $11.72 billion. Minimally invasive approaches are gaining preference because they can reduce surgical trauma, shorten recovery periods, and offer less invasive treatment options for eligible patients. Growing adoption of advanced valve replacement techniques and improvements in surgical technology are supporting the segment's strong position.

Open surgery accounted for the remaining 35.3% of the market, valued at approximately $6.39 billion. It remains an important treatment option for patients who may not be suitable candidates for minimally invasive procedures or who require more extensive surgical intervention. Although its growth rate is lower at 6.8%, continued demand for established surgical approaches keeps open surgery an important part of the overall market.

Aortic Valve Replacement Market Size By Segments

Request Customizationto receive a tailored report.

By End-Use

Ambulatory Surgical Centres are Projected to Register the Fastest Growth at a CAGR of 9.6%

Ambulatory surgical centres are projected to be the fastest-growing end-user segment, with a CAGR of 9.6% during 2026–2034. The segment is benefiting from the increasing shift toward outpatient and shorter-stay procedures, supported by improvements in minimally invasive techniques and post-operative care. As suitable patients increasingly seek procedures that can reduce hospital stays and recovery time, ambulatory facilities are expected to gain a larger role in valve replacement care.

Hospitals accounted for the dominant 84.5% share in 2025, representing approximately $15.3 billion. Hospitals continue to handle the majority of aortic valve replacement procedures because they provide specialized cardiac teams, advanced diagnostic capabilities, intensive care facilities, and comprehensive post-operative support. Ambulatory surgical centres represented 15.5% of the market, valued at around $2.81 billion, and their faster projected growth indicates increasing opportunities for outpatient-based cardiac procedures.

Aortic Valve Replacement Market Share By Segments

Speak to an Analystto discuss market opportunities.

Aortic Valve Replacement Market Regional Outlook

Europe Aortic Valve Replacement Market Analysis

Europe accounted for the largest share of the global aortic valve replacement market, representing 38.6% of total revenue and reaching USD 6.99 billion in 2025. The region continues to lead due to its aging population, well-established cardiovascular healthcare infrastructure, and growing demand for advanced valve replacement procedures. Increasing adoption of minimally invasive techniques, improvements in transcatheter aortic valve replacement, and better access to specialized cardiac care are supporting market growth.

Germany Aortic Valve Replacement Market Insights

Germany represents a major European market, supported by its advanced cardiac care infrastructure and strong adoption of innovative heart valve procedures. Increasing prevalence of aortic stenosis among older adults and growing use of minimally invasive replacement techniques continue to create market opportunities.

United Kingdom Aortic Valve Replacement Market Insights

The UK market is supported by expanding access to specialized cardiac services, increasing demand for advanced valve replacement procedures, and improvements in cardiovascular diagnosis. Growing adoption of transcatheter procedures is also contributing to market development.

Europe Aortic Valve Replacement Market Revenue Share 2025

Unlock Regional Insightsto access country-level data, & regional trends.

North America Aortic Valve Replacement Market Analysis

North America accounted for 31.4% of the global aortic valve replacement market, valued at USD 5.69 billion in 2025, and is projected to register the fastest CAGR of 9.1% during the forecast period. The regional market is driven by increasing prevalence of cardiovascular diseases, a growing elderly population, and rapid adoption of minimally invasive cardiac procedures. Continued technological advancements in valve replacement devices and expanding access to specialized cardiac centers are further accelerating market growth.

United States Aortic Valve Replacement Market Insights

The US market represents the largest contributor in North America, supported by advanced cardiac healthcare infrastructure, high adoption of transcatheter procedures, and strong investments in cardiovascular medical technologies. Increasing diagnosis of aortic valve disorders and growing demand for less-invasive treatment options continue to strengthen market growth.

Canada Aortic Valve Replacement Market Insights

Canada's market is supported by an aging population, improving access to cardiovascular care, and increasing adoption of advanced valve replacement technologies. Growing investments in specialized cardiac services are also contributing to market expansion.

Asia Pacific Aortic Valve Replacement Market Analysis

Asia Pacific accounted for 20.8% of the global aortic valve replacement market, reaching USD 3.77 billion in 2025, and is projected to grow at a CAGR of 8.7% during the forecast period. Rising healthcare expenditure, improving cardiac care infrastructure, and increasing awareness of advanced treatment options are driving regional market growth. The growing elderly population and expanding availability of minimally invasive procedures are further supporting demand.

China Aortic Valve Replacement Market Insights

China's market is benefiting from a rapidly aging population, expanding hospital infrastructure, and increasing access to advanced cardiovascular treatments. Growing investments in domestic medical device capabilities and rising adoption of minimally invasive valve procedures are creating additional opportunities.

Japan Aortic Valve Replacement Market Insights

Japan's market is supported by its aging population, advanced healthcare system, and strong demand for treatments for age-related cardiovascular conditions. Increasing adoption of transcatheter procedures and continued medical technology development are supporting market growth.

Middle East & Africa Aortic Valve Replacement Market Analysis

Middle East & Africa accounted for 4.0% of the global aortic valve replacement market, totaling USD 0.72 billion in 2025. Increasing healthcare investments, improving cardiovascular care infrastructure, and growing awareness of advanced cardiac procedures are supporting market development across the region. Expansion of specialized hospitals and greater access to modern valve replacement technologies are expected to create additional opportunities during the forecast period.

UAE Aortic Valve Replacement Market Insights

The UAE market is supported by investments in advanced cardiac hospitals, growing demand for specialized cardiovascular care, and increasing adoption of minimally invasive procedures. Development of medical tourism and advanced healthcare infrastructure is also creating additional opportunities.

Africa Aortic Valve Replacement Market Insights

Africa's market is benefiting from gradual improvements in cardiovascular healthcare infrastructure, increasing awareness of heart valve disorders, and expanding access to specialized medical services. As investments in cardiac centers and advanced treatment technologies increase, opportunities for aortic valve replacement procedures are expected to expand.

List of Key and Emerging Players in Aortic Valve Replacement Market

Key Industry Developments

  • April 2026: JenaValve Technology announced the commercial launch of the Trilogy® Transcatheter Heart Valve System in the United States following U.S. FDA approval, marking the first commercially available transcatheter valve specifically approved for patients with symptomatic severe aortic regurgitation who are at high surgical risk.
  • March 2026: JenaValve Technology received U.S. FDA Premarket Approval (PMA) for the Trilogy® Transcatheter Heart Valve System for the treatment of symptomatic severe native aortic regurgitation in patients at high or greater risk for surgical aortic valve replacement, expanding treatment options in the aortic valve replacement market.
  • January 2026: Edwards Lifesciences announced that it would not proceed with its proposed acquisition of JenaValve Technology following a U.S. court decision, while reaffirming its commitment to advancing transcatheter therapies for aortic valve replacement and aortic regurgitation.
  • August 2025: The U.S. Federal Trade Commission challenged Edwards Lifesciences' proposed acquisition of JenaValve Technology, citing concerns that the transaction would reduce competition in transcatheter aortic valve replacement (TAVR) devices for aortic regurgitation.

Report Scope

Market Metric Details & Data (2025-2034)
Market Size in 2025 USD 18.10 Billion
Market Size in 2026 USD 20.64 Billion
Market Size in 2034 USD 58.89 Billion
CAGR 14% (2026-2034)
Base Year for Estimation 2025
Historical Data2022-2024
Forecast Period2026-2034
Study Period 2022-2034
Dominant Region Europe
Fastest Growing Region North America
Key Market Players Boston Scientific Corporation, Cryolife Inc, Liva Nova PLC, Medtronic, Abbott
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered By Surgery Type, By End-Use
Geographies Covered North America, Europe, APAC, Middle East and Africa, LATAM
Countries Covered US, Canada, UK, Germany, France, Spain, Italy, Russia, Nordic, Benelux, China, Korea, Japan, India, Australia, Taiwan, South East Asia, UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria, Brazil, Mexico, Argentina, Chile, Colombia

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

How big is the aortic valve replacement market?
The global aortic valve replacement market is projected to grow from USD 20.64 billion in 2026 to USD 58.89 billion by 2034, registering a CAGR of 14% during the forecast period 2026–2034.
Europe dominated the global aortic valve replacement market, accounting for a 38.6% market share in 2025.
The leading companies operating in the aortic valve replacement market are Boston Scientific Corporation, Cryolife Inc, Liva Nova PLC, Medtronic, Abbott, and others.

Author's Details


Debashree Bora

Healthcare Lead

 Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.

Her work focuses on assessing treatment landscapes, outsourcing models, technology adoption, market access dynamics, regulatory developments, and competitive positioning across healthcare and life sciences industries. Debashree has consistently supported organizations in understanding market gaps, evaluating revenue potential, developing market entry strategies, and shaping expansion plans across complex and fast evolving healthcare markets.

With a strong analytical foundation and structured research approach, she excels at synthesizing large datasets, stakeholder inputs, and market signals into actionable insights that guide strategic decision making. Her healthcare expertise enables her to connect clinical, commercial, and operational developments with business opportunities, helping stakeholders anticipate shifts and capitalize on emerging growth areas. Debashree’s consulting oriented mindset and deep healthcare industry understanding make her a trusted advisor to businesses navigating dynamic and rapidly evolving healthcare markets.

Report Details
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
custom reports
Need a Tailored Report?
80% of our existing clients ask for tailored reports.
Request Customization
Request Sample Order Report Now

We are featured on: